Reduced odor identification may be tied to increased Alzheimer's disease risk | CDC data show 65% jump in US antidepressant use over 15 years | Study examines potential use of gold nanoparticles in cancer treatment
August 18, 2017
CONNECT WITH SNMMI
News for nuclear medicine and molecular imaging professionals
McGill University researchers found that biological markers of Alzheimer's disease were most apparent among older adults who had the most difficulty determining odors. The findings in the journal Neurology, based on data involving 274 at-risk individuals with an average age of 63, suggest that smell tests could be used as a cheaper alternative in monitoring Alzheimer's progression, but more studies are needed in tracking changes in odor identification in relation to disease progression, researchers said.
Data from the CDC's National Center for Health Statistics showed antidepressant use in the US was up by almost 65% over the last 15 years, increasing to 13% in 2011-2014 from approximately 8% in 1999-2002. Researchers said antidepressant use increased with age for both genders, but women were about twice as likely as men to report using the medications in the past month.
A UK animal study published in the journal Angewandte Chemie found that gold particles catalyzed a directed chemical reaction in zebrafish brains, in addition to activating lung cancer drugs in a petri dish, suggesting that the approach could be used to release drugs inside tumors. "We hope that a similar device in humans could one day be planted by surgeons to activate chemotherapy directly in tumors and reduce harmful effects in healthy organs," said author Asier Unciti-Broceta.
There isn't much evidence that medical marijuana helps with chronic pain or post-traumatic stress disorder, according to a pair of research reviews by the Veterans Health Administration. "The current studies highlight the real and urgent need for high-quality clinical trials in both of these areas," says Vanderbilt University Medical Center psychiatry researcher Sachin Patel.
The FDA approved VBI Vaccines' investigational new drug application for its immunotherapy candidate VBI-1901, which is being developed as a treatment for patients with glioblastoma multiforme. A Phase I/IIa study of the drug is expected to be launched later this year.
EUSA Pharma's Fotivda, or tivozanib, and Eisai's Kisplyx, or lenvatinib, were rejected as treatments for patients with advanced renal cell carcinoma by the UK's National Institute for Health and Care Excellence. NICE draft guidelines show that treatment with Kisplyx plus everolimus has unreliable results from a clinical trial and lack of evidence showing its cost-effectiveness, while Fotivda still needs more research on its efficacy.
A tool has been developed to help clinicians discuss spiritual well-being with cancer patients in palliative care, regardless of the patient's specific religious faith. A report in the European Journal of Cancer Care noted the tool has been validated in 14 countries and 10 languages.
More than 800 ICD-10 code changes that were approved by the CMS and the CDC for fiscal 2017 will be implemented Oct. 1, according to a blog written by Jerris Heaton, marketing coordinator at ChartLogic. These code changes, which include 123 deleted codes, 273 revised codes and 419 added codes, will be in effect through the end of September 2018, according to Heaton.
A study in the Journal of the American Medical Informatics Association showed that 44.3% of inpatient and outpatient facilities have EHR systems that allow providers to open three or more patient records at a time, while 38.3% allow only one record to be open at a time and 17.4% allow two records to be open. Researchers suggested that hospitals may reduce the risk of documentation errors by limiting the number of patient records that providers can open at once.
Registration is now open for a PET/MRI workshop co-provided by SNMMI and the International Society of Magnetic Resonance in Medicine. The workshop, to be offered October 26-29 in Chicago, is designed for MRI and PET physicists (pre- and post-doctoral students), radiologists, and nuclear medicine physicians who use or are interested in becoming involved with PET/MRI. Register by September 28 for the early-bird discount.
Be sure to grab your 2017 Nuclear Medicine Week swig bottle before they're gone! This 17 oz. stainless steel vacuum bottle comes with a screw-on, spill-resistant lid and a wide-mouth opening. It is vacuum sealed and has double-walled construction for insulation of hot and cold liquids. The bottle can keep drinks cold for up to 24 hours and hot up to 12 hours. Get yours today.
There is no waste of any kind in the world that equals the waste from needless, ill-directed and ineffective motions.
Frank Bunker Gilbreth, engineer
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at firstname.lastname@example.org.